Johnson & Johnson (JNJ) is back in focus after a run of upbeat news, including strong fourth quarter and full year 2025 results, fresh 2026 sales guidance, and new FDA approval for DARZALEX FASPRO.

Those updates have come alongside a strong share price run, with a 90 day share price return of 22.01% and a 1 year total shareholder return of 53.93%. This suggests that momentum has been building as investors reassess growth potential and litigation risks.

If Johnson & Johnson’s recent moves have you looking across healthcare, this can be a good moment to scan healthcare stocks for other ideas in the sector.

With the share price up sharply and Johnson & Johnson trading only slightly below the average analyst price target, the key question now is whether the stock still offers value or if markets are already pricing in future growth.

Most Popular Narrative: 1% Overvalued

At a last close of $227.25 versus a most followed fair value estimate of about $224.09, the current price sits slightly above that narrative anchor, which hinges on modestly higher long term growth and a richer earnings multiple.

The Revenue Growth assumption has increased from about 5.34% to roughly 5.81%, reflecting a modestly higher sales growth outlook in the model.

The future P/E has risen slightly from about 24.81x to roughly 25.39x, indicating a small uplift in the multiple applied to Johnson & Johnson's earnings in the updated work.

Curious why a steady revenue glide path and a higher future earnings multiple still support this price tag? The narrative leans on specific growth, margin and valuation assumptions that may surprise you. The full story sits behind those inputs.

Result: Fair Value of $224.09 (OVERVALUED)

However, that story can shift quickly if talc litigation outcomes change materially, or if loss of exclusivity for key drugs pressures revenue and margins more than expected.

Another Lens On Value

While the popular narrative tags Johnson & Johnson as about 1% overvalued at $227.25 versus a $224.09 fair value, our DCF model presents a different perspective, with a future cash flow value of $372.13. That gap points to a significant difference between the valuation implied by the narrative and the one suggested by the cash flows, raising the question of which view more closely reflects how the market will behave.

Build Your Own Johnson & Johnson Narrative

If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can quickly build a custom view of Johnson & Johnson using Do it your way.

A great starting point for your Johnson & Johnson research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Johnson & Johnson is now on your radar, do not stop there. Broaden your watchlist with a few focused stock ideas that match your style.

• Spot fresh growth potential by scanning these 3528 penny stocks with strong financials that pair smaller share prices with stronger balance sheets and fundamentals than you might expect.
• Capture the AI theme more directly by tracking these 24 AI penny stocks that sit at the crossroads of automation, data and long term earnings potential.
• Target stronger income candidates by reviewing these 12 dividend stocks with yields > 3% that may help you build a steadier stream of cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.